Measurement of bevacizumab-insensitive vascular endothelial growth factor-a
AssigneeBoard of Regents, The University of Texas System
InventorsHonami Naora, Song Yi Ko
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.
Claims3
An in vitro method for measuring a level of bevacizumab-insensitive vascular endothelial growth factor-A (VEGF-A) in a biological fluid obtained from a cancer patient, the method comprising:
- (a) determining an amount of biologically active VEGF-A that is present in the biological fluid by
- (i) incubating the biological fluid with a VEGF ligand trap that binds to VEGF-A, and
- (ii) detecting the amount of VEGF-A that is bound to the VEGF ligand trap by contacting the bound VEGF-A with a polyclonal VEGF-A antibody;
- (b) determining an amount of bevacizumab-sensitive VEGF-A that is present in the biological fluid by
- (i) incubating the biological fluid with bevacizumab, and
- (ii) detecting the amount of VEGF-A that is bound to the bevacizumab by contacting the bound VEGF-A with a polyclonal VEGF-A antibody;
- and
- (c) calculating a ΔVEGF value by subtracting the amount of bevacizumab-sensitive VEGF-A from the amount of biologically active VEGF-A, wherein the ΔVEGF value represents the level of bevacizumab-insensitive VEGF-A in the biological fluid,
- wherein the biological fluid is plasma, serum, ascitic fluid, pleural fluid, peritoneal fluid, or urine.
Dependencies are inferred from the claim text.